Hualan Biological Engineering Inc Class A 002007
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 19.04
- Day Range
- CNY 17.90–18.60
- 52-Week Range
- CNY 16.51–24.55
- Bid/Ask
- CNY 18.54 / CNY 18.55
- Market Cap
- CNY 33.91 Bil
- Volume/Avg
- 25.6 Mil / 11.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 26.80
- Price/Sales
- 6.45
- Dividend Yield (Trailing)
- 1.62%
- Dividend Yield (Forward)
- 1.62%
- Total Yield
- 1.62%
Company Profile
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 3,709
- Website
- http://www.hualanbio.com
Comparables
Valuation
|
Metric
|
002007
|
02480
|
02315
|
|---|---|---|---|
Price/Earnings (Normalized) | 26.80 | — | — |
Price/Book Value | 2.91 | 5.09 | 3.82 |
Price/Sales | 6.45 | — | 4.17 |
Price/Cash Flow | 32.96 | — | — |
Price/Earnings
002007
02480
02315
Financial Strength
|
Metric
|
002007
|
02480
|
02315
|
|---|---|---|---|
Quick Ratio | 2.68 | 13.22 | 1.02 |
Current Ratio | 4.01 | 13.27 | 1.30 |
Interest Coverage | 140.38 | −200.71 | −5.27 |
Quick Ratio
002007
02480
02315
Profitability
|
Metric
|
002007
|
02480
|
02315
|
|---|---|---|---|
Return on Assets (Normalized) | — | −14.55% | −13.53% |
Return on Equity (Normalized) | — | −16.16% | −37.28% |
Return on Invested Capital (Normalized) | — | −16.01% | −20.22% |
Return on Assets
002007
02480
02315
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mgxrcjnrt | Nvfm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jrmjrmr | Xzctvp | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mqpqyzxh | Xykxm | $97.8 Bil | |
MRNA
| Moderna Inc | Qjscnjn | Nffz | $41.3 Bil | |
ARGX
| argenx SE ADR | Pryqplfk | Kjlw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gndysvn | Wndk | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Skgjsqq | Fbfzbm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Njqcyjnfw | Xhfprzh | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mysrkclyjv | Qdprvk | $12.5 Bil | |
INCY
| Incyte Corp | Gslrshs | Bdhbyd | $11.6 Bil |